Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.63 |
| ▸ | CA9 | Q16790 | 9/20 | 0.63 |
| ▸ | CA1 | P00915 | 7/20 | 0.63 |
| ▸ | CA2 | P00918 | 6/20 | 0.63 |
| ▸ | CA3 | P07451 | 6/20 | 0.63 |
| ▸ | CA4 | P22748 | 6/20 | 0.63 |
| ▸ | CA5A | P35218 | 6/20 | 0.63 |
| ▸ | CA7 | P43166 | 6/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.63 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.63 |
| ▸ | CA6 | P23280 | 5/20 | 0.63 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16271239 | 0.90 | SRD5A1 (0.60) | CA12CA9CA1CA2CA3 | |
| SCHEMBL4926628 | 0.86 | CA12 (0.67) | CA12CA9CA1CA2CA3 | |
| SCHEMBL22722364 | 0.78 | CA12 (0.56) | CA12CA9CA1CA2CA3 | |
| SCHEMBL8750141 | 0.77 | CA12 (0.69) | CA12CA9CA1CA2CA3 | |
| SCHEMBL31741273 | 0.77 | CA12 (0.69) | CA12CA9CA1CA2CA3 | |
| SCHEMBL28776384 | 0.77 | CA12 (1.00) | CA12CA9CA1CA2CA3 | |
| SCHEMBL10350668 | 0.77 | CA12 (1.00) | CA12CA9CA1CA2CA3 | |
| SCHEMBL3663606 | 0.77 | CA12 (0.69) | CA12CA9CA1CA2CA3 | |
| SCHEMBL24017191 | 0.77 | CA12 (0.60) | CA12CA9CA1CA2CA3 | |
| Acrylic Acid SCHEMBL10351512 | 0.77 | CA12 (0.77) | CA12CA9CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041289-A1 | COMPOSITIONS AND METHODS FOR ENHANCING OR TREATING FEMALE SEXUAL RESPONSE | T K INC APS (DK) | 2023-02-09 | — | — | US | disclosed |
| US-10266503-B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-23 | — | — | US | disclosed |
| US-9968632-B2 | Fast acting joint relief formulations | NATURES PRODUCTS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9956310-B2 | Time indicator tampon | MARTELLO, JOHN J. | 2018-05-01 | — | — | US | disclosed |
| US-20180055874-A1 | FAST ACTING JOINT RELIEF FORMULATIONS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2018-03-01 | — | — | US | disclosed |
| US-9808483-B2 | Fast acting joint relief formulations | NATURES PRODUCTS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170049804-A1 | FAST ACTING JOINT RELIEF FORMULATIONS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2017-02-23 | — | — | US | disclosed |
| US-9486476-B2 | Fast acting joint relief formulations | Natures Products, Inc (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160038531-A1 | FAST ACTING JOINT RELIEF FORMULATIONS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2016-02-11 | — | — | US | disclosed |
| US-20150217019-A1 | TIME INDICATOR TAMPON | MARTELLO, JOHN J | 2015-08-06 | — | — | US | disclosed |
| US-8128972-B2 | Compositions and methods for enhancing and treating female sexual response | SEMPRAE LABORATORIES, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110117228-A1 | COMPOSITIONS AND METHODS FOR ENHANCING AND TREATING FEMALE SEXUAL RESPONSE | SEMPRAE LABORATORIES, INC. | 2011-05-19 | — | — | US | disclosed |
| US-7875299-B2 | Borage seed oil and angelica pubescens root; topical | SEMPRAE LABORATORIES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20070244326-A1 | SELF-INDICATING PHOTO-REPATTERNABLE HYBRID MATERIALS AND POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-10-18 | — | — | US | disclosed |
| EP-1328281-B1 | COMPOSITIONS AND METHODS FOR TREATING FEMALES SEXUAL RESPONSE | QUALILIFE PHARMACEUTICALS INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20040202739-A1 | Compositions and methods for treating female sexual response | SEMPRAE LABORATORIES, INC. | 2004-10-14 | — | — | US | disclosed |
| US-6737084-B2 | Compositions and methods for enhancing or treating female sexual response | QUALILIFE | 2004-05-18 | — | — | US | disclosed |
| EP-1328281-A1 | COMPOSITIONS AND METHODS FOR TREATING FEMALES SEXUAL RESPONSE | Qualilife Pharmaceuticals Inc. (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020034557-A1 | Compositions and methods for treating female sexual response | SEMPRAE LABORATORIES, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002000240-A2 | COMPOSITIONS AND METHODS FOR TREATING FEMALES SEXUAL RESPONSE | QUALILIFE PHARMACEUTICALS INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244326-A1 | SELF-INDICATING PHOTO-REPATTERNABLE HYBRID MATERIALS AND POLYMERS | PNN, PUF60, UBQLN2 | CA12 3725/4885CA9 4191/4885CA1 3779/4885 |
| US-10266503-B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | YAP1, ICOSLG, SPIN3 | CA12 3008/4885CA9 3833/4885CA1 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.